Strata Critical Medical (SRTA) Net Cash Flow (2019 - 2026)

Strata Critical Medical (SRTA) has 8 years of Net Cash Flow data on file, last reported at $27.8 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at $27.8 million, up 74.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $23.8 million (up 1072.34% YoY), and the FY2025 annual result was $11.9 million, up 228.3% from the prior year.
• Net Cash Flow climbed to $27.8 million in Q1 2026 per SRTA's latest filing, from $8.2 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $185.0 million in Q2 2022 and troughed at -$36.7 million in Q3 2025.
• A 5-year average of $13.4 million and a median of -$607000.0 in 2023 frame the typical range for Net Cash Flow.
• On a YoY basis, Net Cash Flow climbed as much as 1593.41% in 2024 and fell as far as 589.78% in 2024.
• A 5-year view of Net Cash Flow shows it stood at $185.0 million in 2022, then tumbled by 105.01% to -$9.3 million in 2023, then soared by 82.2% to -$1.6 million in 2024, then surged by 597.94% to $8.2 million in 2025, then jumped by 237.82% to $27.8 million in 2026.
• Business Quant data shows SRTA's Net Cash Flow at $27.8 million in Q1 2026, $8.2 million in Q4 2025, and -$36.7 million in Q3 2025.